Grand Pharmaceutical Group Limited (Grand Pharma) reported that every item on the agenda at its Annual General Meeting held on 5 June 2026 was approved by poll, clearing the way for a cash dividend, refreshed board mandates and updated bye-laws.

All nine resolutions—seven ordinary and one special—garnered at least 97.21 % support, with no recorded abstentions. Shareholders holding 3.55 billion shares, the entire issued share capital, were entitled to vote.

Key outcomes:

1. Final dividend • A cash dividend of HK$0.169 per share for the year ended 31 December 2025 received unanimous backing, with 1.98 billion votes in favour.

2. Board composition • Executive Director and CEO Zhou Chao was re-elected with 99.43 % approval. • Independent Non-Executive Directors Hu Yebi and Dr Pei Geng were re-elected with 99.12 % and 98.57 % support, respectively, the latter despite a tenure exceeding nine years. • Directors’ remuneration remains under the Board’s authority, endorsed by 99.95 % of votes.

3. Auditor re-appointment • HLB Hodgson Impey Cheng Limited will continue as auditor, supported by 99.77 % of votes.

4. Capital mandates • General mandate to issue new shares: 97.21 % approval. • Share repurchase mandate: 100 % approval. • Extension of the issue mandate (adding repurchased shares): 97.25 % approval.

5. Governance update • A special resolution to amend and adopt new bye-laws passed with 99.74 % support, exceeding the 75 % threshold.

Attendance The AGM was physically attended by CEO Zhou Chao, while Chairman Dr Tang Weikun and the remaining executive and independent non-executive directors joined via telephone. The company’s auditor served as scrutineer for the poll.

With the dividend confirmed and mandates renewed, Grand Pharma retains full corporate flexibility heading into the 2026 financial year.